The Clinical Pharmacogenetics Implementation Consortium (CPIC) was formed as a shared project between PharmGKB and the Pharmacogenomics Research Network. CPIC guidelines are peer-reviewed and published in a leading journal (in partnership with Clinical Pharmacology and Therapeutics) with simultaneous posting to PharmGKB with supplemental information/data and updates. Anyone with clinical interests in pharmacogenetics is eligible for membership. CPIC's goal is to address some of the barriers to implementation of pharmacogenetic tests into clinical practice.
One barrier to clinical implementation of pharmacogenetics is the lack of freely available, peer-reviewed, updatable, and detailed gene/drug clinical practice guidelines. CPIC provides guidelines that enable the translation of genetic laboratory test results into actionable prescribing decisions for specific drugs. The guidelines can center on genes (e.g. thiopurine methyltransferase and its implications for thiopurines) or around drugs (e.g. warfarin and CYP2C9 and VKORC1). Priority is given to genotyping tests that are already offered in CLIA-approved clinical settings.
More information can be found on the CPIC website:
Questions? Send email to email@example.com.